RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. - Wikidata - awgldk - TriplyDB

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

http://www.wikidata.org/entity/Q36891050

about

One mouse, one patient paradigm: New avatars of personalized cancer therapy mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.The phosphoinositide 3-kinase pathway and therapy resistance in cancer RSK3: A regulator of pathological cardiac remodeling The future of patient-derived tumor xenografts in cancer treatment.Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.A pan-cancer proteomic perspective on The Cancer Genome Atlas.Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models RSK1 activation promotes invasion in nodular melanoma.Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.Phenotyping drug polypharmacology via eicosanoid profiling of blood.PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer Role of NSC319726 in ovarian cancer based on the bioinformatics analyses Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.PI3K/AKT signaling pathway and cancer: an updated review.Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.Drugging PI3K in cancer: refining targets and therapeutic strategies ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer.Comprehensive Analysis of Cancer-Proteogenome to Identify Biomarkers for the Early Diagnosis and Prognosis of Cancer.Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.GCN5 Regulates FGF Signaling and Activates Selective MYC Target Genes during Early Embryoid Body Differentiation.Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer

P2860

Q27023342-2C02CFE5-80D2-4FBC-B629-645562937863 Q27310985-8DA2E26E-91AC-43AE-BA58-AF370CE220D5 Q27853037-B42DCC42-4480-436C-9783-4FCE80F873F4 Q28082811-5EF1D139-7FA2-4A6F-8D0F-B8E7BB2F8847 Q28086916-5631F3A3-9BBE-4AE3-9ED5-2DA7FBFAA534 Q33361578-9EB06999-47F2-4263-9DEA-A3AC82113E0E Q33618850-396311D2-AEDF-4D1A-9718-6C192FC92403 Q33937368-1118049C-DD14-46E4-978B-A6463B30EC25 Q33944976-C70052E2-4081-4858-BE47-5AB7BA40BF4B Q34797680-02919069-C85D-4873-8424-DA3B0398C2BF Q35018805-CA6E3790-5EF9-4C19-925B-E1A27872BFF1 Q35143744-39B33FDF-5E94-43AD-B718-2278AF8F33D0 Q35149656-6F7C0AA5-822D-48EA-A02A-AF36FA354C03 Q35886279-722FFB2A-023B-49B3-8D21-E0B979CD1BD6 Q36245945-EC1CB8B4-0DA8-4EC5-B505-95FE4BAF141A Q36306149-C4071358-48E5-40E5-BAFD-EBA90A0F73EE Q36399060-BFD05F34-7A8E-4B9D-A9CA-70E505055607 Q36765341-9C36F933-C83A-454C-B871-3E0E1B48B608 Q37031949-DB3EF77B-3BC6-4BAF-9679-807A3E593DBF Q37317329-B03353BF-9DB9-4AA8-B861-1C8915606A35 Q38217651-ED399496-D571-483A-94C6-F95815A236C3 Q38238598-6FFF13D2-2698-450B-99A8-351CD8D7816F Q38539217-D99D0960-487A-43A8-B647-2B040125987D Q38727826-CDEF4D90-F9D6-49F3-A407-2DA83B5594A2 Q38764654-090329B6-657B-4C44-B76E-7F84349E8042 Q38769933-C48D03D6-9D0F-4615-8E08-5332D54759B0 Q38794217-AB6479FA-6060-4E10-9568-8FE5D46B4A47 Q39040565-AAD4592A-D9A5-44C8-B71F-130D8E6944CD Q47606195-3DBC1D17-AF9C-4441-B3AF-F6389B027FCD Q47670776-E77B6593-E3DA-4F81-8739-D593E87BFDB5 Q49216777-68389553-D118-41EC-82A2-54E9540573F0 Q52356988-A8FEF673-7356-42B0-A495-FCC482E97A6B Q58712237-52D3B5D5-F2CF-4B0D-A332-FF71927E5028

P2860

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

http://www.wikidata.org/entity/Q36891050

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

@en

type

label

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

@en

prefLabel

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

@en

P1433

Q36891050-24CD73F6-2CFE-4336-B0F1-05CE60AA5A61

P1476

Q36891050-BF7DBEF3-4A10-4D3C-B61A-6A4110869692

P2093

Q36891050-1A08F19A-C17D-4E99-AF41-EA8B37706998

Q36891050-20417E67-138C-415E-8594-C18AB1BF71EF

Q36891050-20CE60EE-F680-4A55-B713-898C5881C6D4

Q36891050-3B599584-7019-486D-A385-0AD712C45759

Q36891050-45A89205-CC95-4AB3-92A5-E899D039F6CB

Q36891050-4B2FB05B-19E9-4979-B083-8A2CEFD03DA9

Q36891050-4B703A89-A119-4270-B0F6-5B12F69B6976

Q36891050-66A732B6-BFA5-47F4-801E-25329BEA2114

Q36891050-6E4CEAFE-2AB1-478F-97FF-B8444D2C18E8

Q36891050-805B694C-2EFF-4FD0-A050-172DDE65096B

P2860

Q36891050-0F5CCC90-EE5B-4D15-AB0C-3053024B7079

Q36891050-19B40046-876A-4D6D-8986-0B204EB038B8

Q36891050-19FF554D-C2A6-46E5-BA8D-0FAE9C7B703D

Q36891050-1BC4AA99-B4A5-434F-9096-AF75A6C89162

Q36891050-2416C106-8AF5-4871-9B86-EB5D22D658DD

Q36891050-2533E4A0-40D2-4D71-8DCA-5BA89E8E74CE

Q36891050-265B2313-67A3-416D-94C2-3C5506FF596B

Q36891050-30979E57-5AE8-4961-9F88-8E7BBE930ED2

Q36891050-32A3A659-DE27-4773-9CA9-11B77AC0FD03

Q36891050-33EF9F39-8EE9-4FFB-BF1A-AA84B8379CE5

P304

Q36891050-4D40E182-FE97-4616-9F2C-5BDAA38C28A5

P31

Q36891050-C042DF05-C6F1-466E-8A80-8C81A52EB1C2

P356

Q36891050-C9E80AFA-D986-4BCB-85DB-33FAEC88CB23

P407

Q36891050-D6229C19-4E65-4C76-916C-D55DB523D89A

P433

Q36891050-F9400FD3-6DC1-4314-B9E1-A690A4856394

P478

Q36891050-9CA9762A-CEB4-4725-8599-077A93A9DBE9

P50

Q36891050-5E2B2BAC-6903-4475-AB9A-BA035CD0AC80

Q36891050-EFB8193D-0EC0-4230-B864-E8825AC10B8E

P577

Q36891050-7ABD82C1-E1E2-41A6-A4C2-FE06B2DB47FC

P698

Q36891050-2768B212-8B71-42B8-A6D8-4528FE9F7829

P932

Q36891050-21CFF5FB-D60D-41A6-8090-463D1C66A9FE

P356

P1433

Journal of Clinical Investigation

P1476

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

@en

P2093

Celina García-García

http://www.w3.org/2001/XMLSchema#string

Gertrudis Sánchez

http://www.w3.org/2001/XMLSchema#string

Joaquín Arribas

http://www.w3.org/2001/XMLSchema#string

Josep-Lluís Parra

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

José Pérez-Garcia

http://www.w3.org/2001/XMLSchema#string

Ludmila Prudkin

http://www.w3.org/2001/XMLSchema#string

Maurizio Scaltriti

http://www.w3.org/2001/XMLSchema#string

Olga Rodríguez

http://www.w3.org/2001/XMLSchema#string

Pieter J A Eichhorn

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer

The RSK family of kinases: emerging roles in cellular signalling

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Targeting the PI3K signaling pathway in cancer

A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3

The selectivity of protein kinase inhibitors: a further update

P304

2551-2563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI66343

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23635776

http://www.w3.org/2001/XMLSchema#string

P932

3668839

http://www.w3.org/2001/XMLSchema#string